ATE428403T1 - Stabilisierte azithromycin-zusammensetzungen - Google Patents

Stabilisierte azithromycin-zusammensetzungen

Info

Publication number
ATE428403T1
ATE428403T1 AT02801784T AT02801784T ATE428403T1 AT E428403 T1 ATE428403 T1 AT E428403T1 AT 02801784 T AT02801784 T AT 02801784T AT 02801784 T AT02801784 T AT 02801784T AT E428403 T1 ATE428403 T1 AT E428403T1
Authority
AT
Austria
Prior art keywords
azithromycin
compositions
stabilized
stabilized azithromycin
antioxidant
Prior art date
Application number
AT02801784T
Other languages
English (en)
Inventor
Ruth Tenengauzer
Joseph Schwarz
Julia Hrakovsky
Tania Lessen
Lev Khondo
Mathi Mathivanan
Claude Singer
Michael Pesachovich
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE428403T1 publication Critical patent/ATE428403T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
AT02801784T 2001-10-18 2002-10-18 Stabilisierte azithromycin-zusammensetzungen ATE428403T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33634601P 2001-10-18 2001-10-18
US33193101P 2001-11-21 2001-11-21
US34129501P 2001-12-17 2001-12-17
PCT/US2002/033339 WO2003032922A2 (en) 2001-10-18 2002-10-18 Stabilized azithromycin compositions

Publications (1)

Publication Number Publication Date
ATE428403T1 true ATE428403T1 (de) 2009-05-15

Family

ID=27406829

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02801784T ATE428403T1 (de) 2001-10-18 2002-10-18 Stabilisierte azithromycin-zusammensetzungen

Country Status (12)

Country Link
US (3) US6764997B2 (de)
EP (1) EP1446010B1 (de)
AT (1) ATE428403T1 (de)
AU (1) AU2002335087A1 (de)
CA (1) CA2463619C (de)
DE (1) DE60232005D1 (de)
DK (1) DK1446010T3 (de)
ES (1) ES2324527T3 (de)
HU (1) HUP0402291A2 (de)
IL (1) IL161398A0 (de)
PT (1) PT1446010E (de)
WO (1) WO2003032922A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861413B2 (en) 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
ES2258142T3 (es) 2001-05-22 2006-08-16 Pfizer Products Inc. Nueva forma cristalina.
US20080149521A9 (en) * 2001-10-18 2008-06-26 Michael Pesachovich Methods of stabilizing azithromycin
PL371259A1 (pl) * 2001-12-21 2005-06-13 Pfizer Products Inc. Bezpośrednio sprasowywalne preparaty azytromycyny
NZ532063A (en) * 2001-12-21 2006-03-31 Pfizer Prod Inc Methods for wet granulating azithromycin
RU2283092C2 (ru) * 2002-02-01 2006-09-10 Пфайзер Продактс Инк. Сухие гранулированные композиции азитромицина
CA2517004A1 (en) * 2003-02-19 2004-09-02 Teva Pharmaceutical Industries Ltd. Methods of stabilizing azithromycin during storage by packaging in a gas impermeable container
US20040266997A1 (en) * 2003-03-25 2004-12-30 Michael Pesachovich Degradation products of azithromycin, and methods for their indentification
BRPI0410638A (pt) * 2003-04-17 2006-06-13 Sandoz Ag derivados de azitromicina
EP1648472A2 (de) * 2003-07-01 2006-04-26 Ranbaxy Laboratories, Ltd. Stabile orale zusammensetzungen von azithromycin-monohydrat
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
CA2540104A1 (en) * 2003-09-30 2005-04-07 Solubest Ltd. Water soluble nanoparticles comprising inclusion complexes
ES2600577T3 (es) 2003-12-04 2017-02-09 Bend Research, Inc. Procedimiento de pulverización-solidificación que usa un extrusor para preparar composiciones en multipartículas de fármacos cristalinos
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
CA2591744A1 (en) * 2004-12-21 2006-06-29 Pfizer Products Inc. Stable non-dihydrate azithromycin oral suspensions
US20060198895A1 (en) * 2005-03-07 2006-09-07 Kotliar Eleonora M Azithromycin powder for oral suspension compositions
US8906823B2 (en) * 2007-09-24 2014-12-09 Basf Corporation Pollutant emission control sorbents and methods of manufacture and use
TWI468167B (zh) 2007-11-16 2015-01-11 威佛(國際)股份有限公司 藥學組成物
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
WO2011015219A1 (en) 2009-08-06 2011-02-10 Shifa Pharmed Industrial Group Co. Process for the purification of azithromycin by separation from its thermal degradation products and/or isomers
RU2512683C2 (ru) 2012-06-08 2014-04-10 Общество с ограниченной ответственностью "ВИК-здоровье животных" Антибактериальная инъекционная фармацевтическая композиция
CN118105392A (zh) * 2017-04-28 2024-05-31 自由生物有限公司 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型
RU2666607C1 (ru) * 2017-05-03 2018-09-11 Общество С Ограниченной Ответственностью "Вик - Здоровье Животных" Способ повышения стабильности инъекционной фармацевтической композиции
US10792262B1 (en) 2019-07-29 2020-10-06 Saol International Limited Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
US11654124B2 (en) 2019-07-29 2023-05-23 Amneal Pharmaceuticals Llc Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
CN111450065B (zh) * 2020-04-22 2022-04-01 南京嘉晨医药科技有限公司 一种阿奇霉素干混悬剂的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI8110592A8 (en) * 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
US5605889A (en) 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
AU4399396A (en) * 1994-12-19 1996-07-10 Russinsky Limited Compounds
US5872104A (en) 1994-12-27 1999-02-16 Oridigm Corporation Combinations and methods for reducing antimicrobial resistance
CN1205338A (zh) * 1998-05-08 1999-01-20 刘万忠 阿奇霉素水溶性盐的合成新方法及其在医药上的用途
TW546302B (en) * 1998-05-08 2003-08-11 Biochemie Sa Improvements in macrolide production
US6239112B1 (en) 1998-07-09 2001-05-29 Merial, Inc. Water miscible macrolide solutions
SI20639A (sl) * 1998-11-30 2002-02-28 Teva Pharmaceutical Industries Ltd. Etanolat azitromicina, postopek za njegovo pripravo in njegovi farmacevtski sestavki
US6239113B1 (en) * 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
IT1313610B1 (it) * 1999-08-09 2002-09-09 S I F I Societa Ind Farmaceuti Processo per la preparazione di formulazioni acquose per uso oftalmico

Also Published As

Publication number Publication date
HK1067278A1 (en) 2005-04-08
US20040192622A1 (en) 2004-09-30
EP1446010A2 (de) 2004-08-18
US20030176369A1 (en) 2003-09-18
DE60232005D1 (de) 2009-05-28
CA2463619A1 (en) 2003-04-24
US6764997B2 (en) 2004-07-20
IL161398A0 (en) 2004-09-27
US20050106239A1 (en) 2005-05-19
DK1446010T3 (da) 2009-06-22
CA2463619C (en) 2008-05-06
HUP0402291A2 (hu) 2005-03-29
PT1446010E (pt) 2009-06-08
EP1446010A4 (de) 2007-06-13
WO2003032922A3 (en) 2003-10-16
AU2002335087A1 (en) 2003-04-28
WO2003032922A2 (en) 2003-04-24
EP1446010B1 (de) 2009-04-15
ES2324527T3 (es) 2009-08-10

Similar Documents

Publication Publication Date Title
DE60232005D1 (de) Stabilisierte azithromycin-zusammensetzungen
PT1117440E (pt) Composicoes farmaceuticas que contem paclitaxel
ATE226240T1 (de) Xanthangummi enthaltende saure reinigungsmittel
ID26033A (id) Metode penstabilan komposisi bahan farmasi dengan penggunaan khusus dari antioksidan
DE69923471D1 (de) Injizierbare propofol-formulierungen
PL2298287T3 (pl) Stabilizowane kompozycje polipeptydów czynnika VII
ES2130575T3 (es) Composiciones inmunogenicas mejoradas contra la gastrina 17 humana.
ES2180319T3 (es) Utilizacion de derivados de metilenbisoxazolidina y composiciones de los mismos.
CY1105009T1 (el) Συνθεση καχαλαλιδης f
DK1635792T3 (da) Stabile farmaceutiske sammensætninger af 2-aza-bicyklo-3.3.0-oktan-3-carboxylsyrederivater
CO5580729A2 (es) Composiciones nutricionales que comprenden cistationina
BRPI0403461A (pt) composições estabilizadas contendo um agente ativo lábil ao oxigênio
ITRM20030363A1 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
DE59903759D1 (de) Ektoparasitizide mittel
HRP20020071B1 (hr) Farmaceutske kompozicije i pripravljanje istih
ATE545434T1 (de) Stabilisierte zusammensetzungen
EP1541134A3 (de) Stabilisierte Azithromycin-Zusammensetzungen
DK1444247T3 (da) Tibolonformuleringer
TNSN03036A1 (en) Stabilized brivudine topical formulations
MXPA03010821A (es) Composiciones de aroma y fragancias.
ATE208627T1 (de) Orale zusammensetzungen mit niedrigdosierten zytotoxischen proteinen
AU2001287673A1 (en) Novel trioxepan compounds
BR0214244A (pt) Uso de uma ascomicina
DE60212101D1 (de) Alanin-2,6-dialkoxyphenylesterderivate als hypnotika
ECSP003412A (es) Derivados de 3- amino -3-arilpropan - 1 - ol, su preparacion y su uso

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties